Compare · head to head
Aurinia Pharmaceuticals vs Medpaces
Medpaces ranks higher overall — 360 rank 96 vs 85.
Aurinia Pharmaceuticals leads on Value (60 vs 54). Medpaces leads on Quality (83 vs 74) and Growth (64 vs 48). The two are close on Safety and Sentiment.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | Canada | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Life Sciences Tools & Services |
| Size | Small | Large |
| ISIN | CA05156V1022 | US58506Q1094 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | ||
| Ranks | ||
| 360 | 85 | 96 |
| Value | 60 | 54 |
| Quality | 74 | 83 |
| Growth | 48 | 64 |
| Safety | 61 | 63 |
| Sentiment | 45 | 43 |
| Quality details | ||
| Profitability | 95 | 95 |
| Cash Truth | 52 | 71 |
Aurinia Pharmaceuticals vs Vera TherapeuticsAurinia Pharmaceuticals vs Tenaya TherapeuticsAurinia Pharmaceuticals vs Metagenomi TherapeuticsAurinia Pharmaceuticals vs CertaraAdd a third stock →
Full analyses: Aurinia Pharmaceuticals · Medpaces
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100